- Home
- BFRG vs LPCN Comparison
BFRG vs LPCN Comparison
Compare BFRG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRG
- LPCN
- Stock Information
- Founded
- BFRG 2017
- LPCN 1997
- Country
- BFRG United States
- LPCN United States
- Employees
- BFRG N/A
- LPCN N/A
- Industry
- BFRG Retail: Computer Software & Peripheral Equipment
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- BFRG Technology
- LPCN Health Care
- Exchange
- BFRG Nasdaq
- LPCN Nasdaq
- Market Cap
- BFRG 16.4M
- LPCN 16.1M
- IPO Year
- BFRG 2023
- LPCN N/A
- Fundamental
- Price
- BFRG $1.14
- LPCN $2.89
- Analyst Decision
- BFRG
- LPCN Strong Buy
- Analyst Count
- BFRG 0
- LPCN 2
- Target Price
- BFRG N/A
- LPCN $9.00
- AVG Volume (30 Days)
- BFRG 92.3K
- LPCN 16.1K
- Earning Date
- BFRG 08-13-2025
- LPCN 11-06-2025
- Dividend Yield
- BFRG N/A
- LPCN N/A
- EPS Growth
- BFRG N/A
- LPCN N/A
- EPS
- BFRG N/A
- LPCN N/A
- Revenue
- BFRG $33,257.00
- LPCN $4,208,119.00
- Revenue This Year
- BFRG N/A
- LPCN N/A
- Revenue Next Year
- BFRG N/A
- LPCN N/A
- P/E Ratio
- BFRG N/A
- LPCN N/A
- Revenue Growth
- BFRG N/A
- LPCN N/A
- 52 Week Low
- BFRG $1.09
- LPCN $2.68
- 52 Week High
- BFRG $4.84
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- BFRG 33.22
- LPCN 39.07
- Support Level
- BFRG $1.18
- LPCN $2.86
- Resistance Level
- BFRG $1.27
- LPCN $3.00
- Average True Range (ATR)
- BFRG 0.06
- LPCN 0.12
- MACD
- BFRG -0.00
- LPCN -0.01
- Stochastic Oscillator
- BFRG 21.01
- LPCN 12.28
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. Its platform technology, named, bfLEAP, is an analytical AI/ML platform that is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise1, multi-dimensional understanding of its data.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.